Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut

Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut

2 weeks from now

Sep 13, 2024  · Shares of Moderna fell Friday after taking on steep losses a day earlier on the news that it plans to cut research and development spending by $1.1 billion by 2027.

investopedia.com

Moderna's Spending Cuts, Pipeline Shakeup Leave Doubts About A …

2 weeks from now

Sep 13, 2024  · The J.P. Morgan analysts downgraded Moderna's stock to underweight from neutral, and cut their price target to $70, from $88. Moderna's stock is down 33% in the year to …

morningstar.com

Moderna Shares Plunge On Plans To Cut $1.1 Billion In Costs, Launch …

2 weeks from now

Sep 12, 2024  · Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

cnbc.com

Moderna’s Spending Cuts, Pipeline Shakeup Leave Doubts About A …

2 weeks from now

The J.P. Morgan analysts downgraded Moderna’s stock to underweight from neutral, and cut their price target to $70, from $88. Moderna’s stock is down 33% in the year to date, while the S&P …

msn.com

StockWatch: Moderna's $1.1B R&D Cut, Profitability Delay Jolt …

2 weeks from now

Sep 16, 2024  · Over the next three years, Moderna added, it will cut about between $1 billion and $1.2 billion in expenses by shrinking its R&D budget by about 20%, going from the $4.8 billion …

genengnews.com

Moderna Faces Analyst Downgrades Amid Revised R&D …

2 weeks from now

Sep 13, 2024  · Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten …

yahoo.com

Moderna Crashes After Slashing Its R&D Budget By $1.1 Billion

2 weeks from now

Sep 16, 2024  · Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget by $1.1 billion and issued light 2025 sales guidance. The company says its investment …

investors.com

Moderna's Stock Slides As It Slashes Research Spending, Trims Pipeline

2 weeks from now

Sep 12, 2024  · Moderna Inc.'s stock fell more than 18% Thursday after the company said it will rein in its research-and-development spending and trim its pipeline as it looks to shake off the …

morningstar.com

Moderna To Cut R&D Spending $1.1 B - STAT

2 weeks from now

Sep 12, 2024  · Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who …

statnews.com

Moderna To Slash Costs By $1.1B - LinkedIn

2 weeks from now

Sep 12, 2024  · Moderna, the biotech company known for developing one of the COVID-19 vaccines, plans to cut $1.1 billion in expenses by 2027 as it adjusts its business in the post …

linkedin.com

Moderna Will Cut $1.1bn Off Its Annual R&D Spend

2 weeks from now

Jan 27, 2025  · Moderna says it will cut $1.1bn off its annual R&D spend ... Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its …

pharmaphorum.com

Moderna To Cut Costs, Trim Pipeline In R&D Revamp

2 weeks from now

Sep 12, 2024  · Dive Brief: Moderna will cut R&D spending by 20% and trim its pipeline as part of a strategic overhaul that will shift its research focus and put more resources into products that …

biopharmadive.com

Moderna Faces Analyst Downgrades Amid Revised R&D …

2 weeks from now

Sep 14, 2024  · Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten …

aol.com

JPM25: Moderna Slashes Guidance, Plots $1B In Cost Cuts This Year …

2 weeks from now

Jan 13, 2025  · The company has reduced its revenue guidance for 2025, as well, forecasting sales to land between $1.5 billion and $2.5 billion this year. The big biotech previously hoped …

fiercepharma.com

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are …

2 weeks from now

Goldman’s price-target cut is Moderna’s third in just a few days. On Monday, Evercore analysts lowered their price target to $50 from $60. On Friday, J.P. Morgan lowered its call to $40 from …

msn.com